TickerTalks
Browse all tickers →
TickerTalks›$IOVA
IOIOVA

Iovance Biotherapeutics, Inc.

$IOVA·$1.5B·Biotechnology·Healthcare
$5.48+9.2%YTD+97.1%1Y+120.1%
Mentions · last 7 days
2026-07-14: 158 posts2026-07-15: 356 posts2026-07-16: 318 posts2026-07-17: 279 posts2026-07-18: 18 posts2026-07-19: 53 posts2026-07-20: 47 posts1,239-1%
Price updated 1h ago·X counts updated 1d ago
IOIOVA
$IOVAIovance Biotherapeutics, Inc.
$5.48+9.16%1.2k posts-1%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $IOVA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeAcceleratingAI verdict · as of 2026-07-20

The move is getting stronger, with heavier trading behind it.

TIL-therapy pioneer breaks out on volume as short interest keeps unwinding.

Iovance Biotherapeutics developed and commercialized Amtagvi — the only FDA-approved TIL (tumor-infiltrating lymphocyte) cell therapy for metastatic melanoma. It's up 114% over the past year and just broke out on 3x normal volume with real short-covering as the NSCLC (lung cancer) data readout approaches.

The setup:

  • The commercial launch is finally getting traction: Q1 revenue $71M (+45% YoY) — small in absolute terms, but this is a bespoke cell therapy priced at $515K per patient, so the revenue ramp is a direct read on center authorization pace and manufacturing throughput — both were the bottleneck before now.
  • The NSCLC readout is the transformative catalyst: comprehensive non-small-cell lung cancer data due before year-end, which would materially expand the addressable market from ~7,000 US melanoma patients to hundreds of thousands of NSCLC patients — this is why price targets are running $8-$12+ and buyout scenarios are being modeled at $12.80.
  • Short interest is unwinding into the breakout: reported consistent decline since mid-February, and the technical structure (ascending channel, 3x volume breakout at $5) reflects covering pressure rather than fresh long-only buying — that pattern usually needs a fresh catalyst to sustain, so NSCLC data becomes even more binary.

Accelerating with visible short-covering plus a dated readout is a strong setup. Aug 6 Q2 gives the operational read; NSCLC data before year-end is the trigger. A revenue beat plus positive NSCLC breaks toward $8+; a delayed readout breaks the ascending channel back to $3.50.

Agrees with X sentimentThe X 'honey badger of biotech' framing on the tape structure is a fair descriptor — indifferent to the Nasdaq selloff is what accelerating with a real catalyst looks like. The NSCLC readout timing and the $12.80 buyout scenario framing map to the actual catalyst calendar.

What to watch: Aug 6 Q2 earnings for Amtagvi ramp trajectory, and NSCLC comprehensive readout before year-end. Positive NSCLC data breaks toward $8+ and opens the buyout conversation; a delay would break the ascending channel back to $3.50.

On the calendar: 2026-08-06 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment60 posts analyzed · as of 2026-07-20

Iovance Biotherapeutics chatter is uniformly constructive on the breakout from around $4 to $5 on elevated volume, framed as a short-squeeze setup with borrow costs slowly climbing and short interest near 26%. Bulls anchor on Amtagvi as the only FDA-approved TIL therapy for metastatic melanoma, upcoming NSCLC lung-cancer data in H2, and Wells Fargo channel checks suggesting a Q2 revenue beat. Longs cite Wayne Rothbaum's directorship, TIL platform durability, and price targets stretching from $8-10 toward double digits.

Read the AI verdict + X sentiment for $IOVA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops tumor-infiltrating lymphocyte cell therapies for solid tumors, with Amtagvi approved for advanced melanoma.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IOVA.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $IOVA

Neutral — Develops tumor-infiltrating lymphocyte cell therapies for solid tumors, with Amtagvi approved for advanced melanoma; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.6%YTD
+46.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-45.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-127%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-20.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-50.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
115%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.19$-0.190.0%
Q4 2025Feb 24, 2026$-0.18$-0.22+18.2%
Q3 2025Nov 6, 2025$-0.25$-0.29+13.8%
Q2 2025Aug 7, 2025$-0.33$-0.29-13.8%
Next earningsThu, Aug 6·consensus EPS $-0.17

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$71.4M+44.8%98.6%-113%$-0.19$-78.7M
Q4 FY25$86.8M+17.7%216%-84.7%$-0.15$-61.9M
Q3 FY25$67.5M+15.2%97.9%-141%$-0.25$-89.5M
Q2 FY25$60.0M+92.7%5.5%-190%$-0.33$-74.9M

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$362.1M$355.0M – $371.5M-$0.55-$0.64 – -$0.356
FY27$496.2M$482.6M – $510.7M-$0.31-$0.36 – -$0.246
FY28$740.3M$738.3M – $742.3M$0.00-$0.01 – $0.016
FY29$987.2M$942.7M – $1.0B$0.21$0.20 – $0.235
FY30$1.2B$1.2B – $1.3B$0.43$0.40 – $0.463

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.84%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+23.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+57.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 299.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today5.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.695-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 49 other (19 exempts · 19 inkinds · 11 awards) in window

See when $IOVA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-3ASRAuto-shelf registrationJun 18S-3ASR
AI summary

Iovance Biotherapeutics (IOVA) filed an automatic shelf registration statement (Form S-3ASR) on June 18, 2026, effective immediately upon filing under Rule 462(e) as a well-known seasoned issuer. Interim CEO Frederick G. Vogt signed the filing; the company is headquartered in San Carlos, CA. The shelf enables future securities offerings at Iovance's discretion; no specific offering amount or timing was disclosed.

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote · Item 8.01: Other event
AI summary

Iovance Biotherapeutics held its 2026 Annual Meeting on June 10, 2026, with ~74% of shares represented. Stockholders voted on seven proposals including election of six directors, advisory say-on-pay, frequency of future say-on-pay votes, ratification of Ernst & Young LLP as auditor, a 1,000,000-share ESPP increase, and an increase to authorized shares of common stock (the exact count and results are in the attachments). The authorized share increase is mildly dilutive optionality; remaining items are routine governance.

8-KOfficer or director changeMar 208-K — Item 5.02: Officer or director change
AI summary

IOVA disclosed a personnel change (8-K Item 5.02, dated 2026-03-20). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 14 other (3 13Gs · 2 S-8s · 2 proxys · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)globenewswire.com·4d agoIovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)seekingalpha.com·5d agoThis Stock Is Up 74% This Year: Is It Too Late to Buy?fool.com·13d agoHeartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?fool.com·18d agoAmgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?fool.com·28d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$ATAI$QTTB$MRNA$AGEN$SLS$IBRX$ALLO
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport